DE68924783T2
(de)
*
|
1988-09-30 |
1996-03-28 |
Neorx Corp |
Wässrige additivsysteme, verfahren und polymerteilchen.
|
US5066789A
(en)
*
|
1988-09-30 |
1991-11-19 |
Neorx Corporation |
Targeting substance-diagnostic/therapeutic agent conjugates having Schiff base linkages
|
US5576288A
(en)
*
|
1989-04-27 |
1996-11-19 |
The Salk Institute For Biological Studies |
Fibroblast growth factor conjugates
|
US5154924A
(en)
*
|
1989-09-07 |
1992-10-13 |
Alkermes, Inc. |
Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
|
US6329508B1
(en)
|
1989-09-07 |
2001-12-11 |
Alkermes, Inc. |
Transferrin receptor reactive chimeric antibodies
|
US5977307A
(en)
*
|
1989-09-07 |
1999-11-02 |
Alkermes, Inc. |
Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins
|
US5182107A
(en)
*
|
1989-09-07 |
1993-01-26 |
Alkermes, Inc. |
Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
|
US5672683A
(en)
*
|
1989-09-07 |
1997-09-30 |
Alkermes, Inc. |
Transferrin neuropharmaceutical agent fusion protein
|
US5527527A
(en)
*
|
1989-09-07 |
1996-06-18 |
Alkermes, Inc. |
Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
|
US6610299B1
(en)
|
1989-10-19 |
2003-08-26 |
Aventis Pharma Deutschland Gmbh |
Glycosyl-etoposide prodrugs, a process for preparation thereof and the use thereof in combination with functionalized tumor-specific enzyme conjugates
|
US7241595B2
(en)
*
|
1989-10-20 |
2007-07-10 |
Sanofi-Aventis Pharma Deutschland Gmbh |
Glycosyl-etoposide prodrugs, a process for preparation thereof and the use thereof in combination with functionalized tumor-specific enzyme conjugates
|
US6475486B1
(en)
|
1990-10-18 |
2002-11-05 |
Aventis Pharma Deutschland Gmbh |
Glycosyl-etoposide prodrugs, a process for preparation thereof and the use thereof in combination with functionalized tumor-specific enzyme conjugates
|
US5137877B1
(en)
*
|
1990-05-14 |
1996-01-30 |
Bristol Myers Squibb Co |
Bifunctional linking compounds conjugates and methods for their production
|
GB9017024D0
(en)
*
|
1990-08-03 |
1990-09-19 |
Erba Carlo Spa |
New linker for bioactive agents
|
CA2048089A1
(en)
*
|
1990-09-17 |
1992-03-18 |
Wolfgang A. Wrasidlo |
Chemical conjugation of morpholino anthracyclines to antibodies
|
US5776458A
(en)
*
|
1990-12-05 |
1998-07-07 |
Pharmacia & Upjohn S.P.A. |
Anthracycline-conjugates
|
GB9026491D0
(en)
*
|
1990-12-05 |
1991-01-23 |
Erba Carlo Spa |
Anthracycline-conjugates
|
US5272253A
(en)
*
|
1991-07-01 |
1993-12-21 |
Eli Lilly And Company |
Cluster conjugates of drugs with antibodies
|
US5622929A
(en)
*
|
1992-01-23 |
1997-04-22 |
Bristol-Myers Squibb Company |
Thioether conjugates
|
US5505931A
(en)
*
|
1993-03-04 |
1996-04-09 |
The Dow Chemical Company |
Acid cleavable compounds, their preparation and use as bifunctional acid-labile crosslinking agents
|
GR1001459B
(el)
*
|
1992-10-08 |
1993-12-30 |
Lilly Co Eli |
Σύμπλεγμα συζυγών φαρμάκων με αντισώματα.
|
DE4236237A1
(de)
*
|
1992-10-27 |
1994-04-28 |
Behringwerke Ag |
Prodrugs, ihre Herstellung und Verwendung als Arzneimittel
|
US5556623A
(en)
*
|
1993-03-30 |
1996-09-17 |
Eli Lilly And Company |
Antibody-drug conjugates
|
US6551618B2
(en)
|
1994-03-15 |
2003-04-22 |
University Of Birmingham |
Compositions and methods for delivery of agents for neuronal regeneration and survival
|
DE4435087A1
(de)
*
|
1994-09-30 |
1996-04-04 |
Deutsches Krebsforsch |
Konjugat zur Behandlung von Infektions-, Autoimmun- und Hauterkrankungen
|
US6015555A
(en)
*
|
1995-05-19 |
2000-01-18 |
Alkermes, Inc. |
Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
|
US20030119724A1
(en)
*
|
1995-11-22 |
2003-06-26 |
Ts`O Paul O.P. |
Ligands to enhance cellular uptake of biomolecules
|
US5843903A
(en)
*
|
1995-11-27 |
1998-12-01 |
The Administrators Of The Tulane Educational Fund |
Targeted cytotoxic anthracycline analogs
|
PT871490E
(pt)
*
|
1995-12-22 |
2003-07-31 |
Bristol Myers Squibb Co |
Ligantes de hidrazona ramificada
|
US6759509B1
(en)
|
1996-11-05 |
2004-07-06 |
Bristol-Myers Squibb Company |
Branched peptide linkers
|
AU5159798A
(en)
*
|
1996-11-05 |
1998-05-29 |
Bristol-Myers Squibb Company |
Branched peptide linkers
|
CA2248592A1
(en)
*
|
1998-08-31 |
2000-02-29 |
Christopher D. Batich |
Microspheres for use in the treatment of cancer
|
GB9917012D0
(en)
*
|
1999-07-20 |
1999-09-22 |
Pharmacia & Upjohn Spa |
Combined preparations comprising antitumor agents
|
US20060014684A1
(en)
*
|
2000-03-03 |
2006-01-19 |
University Technologies International Inc. |
Novel uses of EGF
|
US6586207B2
(en)
|
2000-05-26 |
2003-07-01 |
California Institute Of Technology |
Overexpression of aminoacyl-tRNA synthetases for efficient production of engineered proteins containing amino acid analogues
|
AU2001266853B2
(en)
*
|
2000-06-14 |
2005-02-17 |
Medarex, Inc. |
Prodrug compounds with an oligopeptide having an isoleucine residue
|
US6624317B1
(en)
|
2000-09-25 |
2003-09-23 |
The University Of North Carolina At Chapel Hill |
Taxoid conjugates as antimitotic and antitumor agents
|
WO2002043771A2
(en)
|
2000-12-01 |
2002-06-06 |
Cell Works Inc. |
Conjugates of glycosylated/galactosylated peptide
|
AU2002216864A1
(en)
*
|
2000-12-21 |
2002-07-01 |
Mcgill University |
Conjugates of antibodies and anticancer drugs
|
US7445802B2
(en)
*
|
2000-12-26 |
2008-11-04 |
Yeda Research And Development Co. Ltd |
Site-specific in situ generation of allicin using a targeted alliinase delivery system for the treatment of cancers, tumors, infectious diseases and other allicin-sensitive diseases
|
US7829084B2
(en)
*
|
2001-01-17 |
2010-11-09 |
Trubion Pharmaceuticals, Inc. |
Binding constructs and methods for use thereof
|
US7754208B2
(en)
|
2001-01-17 |
2010-07-13 |
Trubion Pharmaceuticals, Inc. |
Binding domain-immunoglobulin fusion proteins
|
US20100056762A1
(en)
|
2001-05-11 |
2010-03-04 |
Old Lloyd J |
Specific binding proteins and uses thereof
|
DK2163256T3
(en)
|
2001-05-11 |
2015-12-07 |
Ludwig Inst For Cancer Res Ltd |
Specific binding proteins and use thereof
|
CA2447335C
(en)
*
|
2001-05-15 |
2011-01-04 |
Faulk Pharmaceuticals, Inc. |
Targeted delivery of drugs for the treatment of viral infections
|
CA2464609A1
(en)
*
|
2001-10-26 |
2003-05-01 |
University Technologies International, Inc. |
Use of egf to inhibit pathogenic infections of the urogenital tract
|
RU2196604C1
(ru)
*
|
2001-12-21 |
2003-01-20 |
Северин Евгений Сергеевич |
Полипептид, являющийся аналогом рецепторсвязывающего фрагмента эпидермального фактора роста с 21-й по 31-ю аминокислоту, его конъюгат с доксорубицином и фармацевтическая композиция на его основе
|
US9770517B2
(en)
|
2002-03-01 |
2017-09-26 |
Immunomedics, Inc. |
Anti-Trop-2 antibody-drug conjugates and uses thereof
|
EP2357006B1
(en)
|
2002-07-31 |
2015-09-16 |
Seattle Genetics, Inc. |
Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
|
WO2004054622A1
(en)
|
2002-12-13 |
2004-07-01 |
Immunomedics, Inc. |
Immunoconjugates with an intracellularly-cleavable linkage
|
DE602004027888D1
(de)
|
2003-02-20 |
2010-08-12 |
Seattle Genetics Inc |
Anti-cd70 antikörper-arzneimittelkonjugate und ihr
|
US20040171175A1
(en)
*
|
2003-02-28 |
2004-09-02 |
Swanson Basil I. |
Process for conjugating biomolecules to hydrophobic membrane-incorporated molecules
|
US20040219099A1
(en)
*
|
2003-05-02 |
2004-11-04 |
Jasbir Sandhu |
Method for the treatment of tumors
|
US20040220121A1
(en)
*
|
2003-05-02 |
2004-11-04 |
Jasbir Sandhu |
Methods for drug delivery
|
US20040219103A1
(en)
*
|
2003-05-02 |
2004-11-04 |
Jasbir Sandhu |
Methods useful for the diagnosis, imaging and treatment of tumors
|
US20040220084A1
(en)
*
|
2003-05-02 |
2004-11-04 |
Jasbir Sandhu |
Methods for nucleic acid delivery
|
US20040219102A1
(en)
*
|
2003-05-02 |
2004-11-04 |
Jasbir Sandhu |
Compositions for drug delivery
|
US20040220085A1
(en)
*
|
2003-05-02 |
2004-11-04 |
Jasbir Sandhu |
Compositions for nucleic acid delivery
|
US20040219100A1
(en)
*
|
2003-05-02 |
2004-11-04 |
Jasbir Sandhu |
Composition useful for the treatment of tumors
|
US20040219104A1
(en)
*
|
2003-05-02 |
2004-11-04 |
Jasbir Sandhu |
Methods for treatment of tumors
|
US20040219101A1
(en)
*
|
2003-05-02 |
2004-11-04 |
Jasbir Sandhu |
Composition useful for treatment of tumors
|
US20040219097A1
(en)
*
|
2003-05-02 |
2004-11-04 |
Jasbir Sandhu |
Composition useful for the diagnosis, imaging and treatment of tumors
|
US20040220390A1
(en)
*
|
2003-05-02 |
2004-11-04 |
Jasbir Sandhu |
Composition useful for the treatment of tumors
|
US9011880B2
(en)
*
|
2003-10-21 |
2015-04-21 |
Igf Oncology, Llc |
Compounds and methods for treating cancer
|
CA2542834C
(en)
*
|
2003-10-21 |
2012-04-24 |
Igf Oncology, Llc |
Conjugates or co-administration of igf-1 receptor ligands with anti-cancer chemotherapeutic agents
|
EP3120861B1
(en)
|
2003-11-06 |
2018-08-15 |
Seattle Genetics, Inc. |
Intermediate for conjugate preparation comprising auristatin derivatives and a linker
|
WO2005072292A2
(en)
*
|
2004-01-24 |
2005-08-11 |
Hugh Mctavish |
Methods for enhancing radiation therapy
|
US20050175619A1
(en)
*
|
2004-02-05 |
2005-08-11 |
Robert Duffy |
Methods of producing antibody conjugates
|
US20050287639A1
(en)
|
2004-05-17 |
2005-12-29 |
California Institute Of Technology |
Methods of incorporating amino acid analogs into proteins
|
JP2008517917A
(ja)
*
|
2004-10-21 |
2008-05-29 |
アイジーエフ オンコロジー エルエルシー |
癌を治療するための毒素および放射性核種結合igf−1受容体リガンド
|
CA2589374C
(en)
|
2004-11-30 |
2016-05-03 |
Curagen Corporation |
Antibodies directed to gpnmb and uses thereof
|
US10058621B2
(en)
|
2015-06-25 |
2018-08-28 |
Immunomedics, Inc. |
Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers
|
US9707302B2
(en)
|
2013-07-23 |
2017-07-18 |
Immunomedics, Inc. |
Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
|
ES2353212T3
(es)
*
|
2005-03-30 |
2011-02-28 |
Saladax Biomedical Inc. |
Inmunoensayo de doxorrubicina.
|
EP2298815B1
(en)
|
2005-07-25 |
2015-03-11 |
Emergent Product Development Seattle, LLC |
B-cell reduction using CD37-specific and CD20-specific binding molecules
|
US8052971B2
(en)
*
|
2005-11-21 |
2011-11-08 |
MG Biologics |
Oral use of specific antibodies for intestinal health
|
CA2643826A1
(en)
*
|
2006-02-27 |
2008-06-12 |
Paul A. Wender |
Compositions and methods for transport of molecules with enhanced release properties across biological barriers
|
CA2647632C
(en)
|
2006-03-27 |
2017-06-27 |
University Of Maryland Biotechnology Institute |
Glycoprotein synthesis and remodeling by enzymatic transglycosylation
|
CA2699837C
(en)
|
2006-12-01 |
2017-06-13 |
Seattle Genetics, Inc. |
Variant target binding agents and uses thereof
|
CN104043123B
(zh)
|
2007-01-25 |
2019-08-13 |
达娜-法勃肿瘤研究所公司 |
抗egfr抗体在治疗egfr突变体介导的疾病中的用途
|
JP5618549B2
(ja)
|
2007-03-15 |
2014-11-05 |
ルードヴィッヒ インスティテュート フォー キャンサーリサーチ リミテッド |
Egfr抗体及びsrc阻害剤を用いる治療方法及び関連製剤
|
SG183023A1
(en)
|
2007-07-16 |
2012-08-30 |
Genentech Inc |
Anti-cd79b antibodies and immunoconjugates and methods of use
|
RU2557319C2
(ru)
|
2007-07-16 |
2015-07-20 |
Дженентек, Инк. |
ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА ПРОТИВ CD79b И ИММУНОКОНЪЮГАТЫ И СПОСОБЫ ПРИМЕНЕНИЯ
|
EP2188311B1
(en)
|
2007-08-14 |
2016-10-05 |
Ludwig Institute for Cancer Research Ltd. |
Monoclonal antibody 175 targeting the egf receptor and derivatives and uses thereof
|
EP2197489B2
(en)
|
2007-10-04 |
2020-04-01 |
ZymoGenetics, Inc. |
B7 family member zb7h6 and related compositions and methods
|
CA2711736A1
(en)
|
2008-01-18 |
2009-07-23 |
Medimmune, Llc |
Cysteine engineered antibodies for site-specific conjugation
|
CN101981055B
(zh)
|
2008-01-31 |
2016-03-09 |
健泰科生物技术公司 |
抗cd79b抗体和免疫偶联物及使用方法
|
US8742076B2
(en)
*
|
2008-02-01 |
2014-06-03 |
Genentech, Inc. |
Nemorubicin metabolite and analog reagents, antibody-drug conjugates and methods
|
WO2010009124A2
(en)
|
2008-07-15 |
2010-01-21 |
Genentech, Inc. |
Anthracycline derivative conjugates, process for their preparation and their use as antitumor compounds
|
WO2010014236A2
(en)
*
|
2008-07-30 |
2010-02-04 |
The University Of North Carolina At Chapel Hill |
Acylhydrazone-based cleavable linkers
|
CA2766405A1
(en)
|
2009-06-22 |
2011-01-13 |
Medimmune, Llc |
Engineered fc regions for site-specific conjugation
|
US9493578B2
(en)
|
2009-09-02 |
2016-11-15 |
Xencor, Inc. |
Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
|
TWI483736B
(zh)
|
2009-10-23 |
2015-05-11 |
Millennium Pharm Inc |
抗-gcc抗體分子及其相關之組合物及方法
|
CN104926942B
(zh)
|
2009-12-09 |
2018-09-14 |
国家健康和医学研究院 |
结合b7h6的单克隆抗体及其用途
|
US8609092B2
(en)
|
2010-02-08 |
2013-12-17 |
Agensys, Inc. |
Antibody drug conjugates (ADC) that bind to 161P2F10B proteins
|
KR101764572B1
(ko)
*
|
2010-03-12 |
2017-08-03 |
이뮤노젠 아이엔씨 |
Cd37―결합 분자 및 이의 면역접합체
|
CN103052649B
(zh)
|
2010-07-29 |
2015-12-16 |
Xencor公司 |
具有修改的等电点的抗体
|
KR20240013851A
(ko)
|
2010-09-29 |
2024-01-30 |
어젠시스 인코포레이티드 |
191p4d12 단백질에 결합하는 항체 약물 컨쥬게이트(adc)
|
EP2621954A1
(en)
|
2010-10-01 |
2013-08-07 |
Oxford Biotherapeutics Ltd. |
Anti-rori antibodies
|
BR112013013127B1
(pt)
|
2010-12-02 |
2021-06-22 |
Nerviano Medical Sciences S.R.L. |
Processo para a preparação de derivados de morfolinil antraciclina, compostos derivados de morfolinil antraciclina e composição farmacêutica compreendendo estes compostos
|
SI3156420T1
(sl)
|
2010-12-06 |
2019-05-31 |
Seattle Genetics, Inc. |
Humanizirana protitelesa za LIV-1 in njihova uporaba pri zdravljenju raka
|
JOP20210044A1
(ar)
|
2010-12-30 |
2017-06-16 |
Takeda Pharmaceuticals Co |
الأجسام المضادة لـ cd38
|
WO2012135740A2
(en)
*
|
2011-04-01 |
2012-10-04 |
Immunogen, Inc. |
Cd37-binding molecules and immunoconjugates thereof
|
FI3415531T3
(fi)
|
2011-05-27 |
2023-09-07 |
Glaxo Group Ltd |
Bcma:aa (cd269/tnfrsf17) sitovia proteiineja
|
WO2013022855A1
(en)
|
2011-08-05 |
2013-02-14 |
Xencor, Inc. |
Antibodies with modified isoelectric points and immunofiltering
|
US20130058947A1
(en)
|
2011-09-02 |
2013-03-07 |
Stem Centrx, Inc |
Novel Modulators and Methods of Use
|
US10851178B2
(en)
|
2011-10-10 |
2020-12-01 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
AU2012323287B2
(en)
|
2011-10-10 |
2018-02-01 |
Xencor, Inc. |
A method for purifying antibodies
|
MX358862B
(es)
|
2011-11-04 |
2018-09-06 |
Zymeworks Inc |
Diseño de anticuerpo heterodimérico estable con mutaciones en el domino fc.
|
EP2592103A1
(en)
|
2011-11-08 |
2013-05-15 |
Adriacell S.p.A. |
Polymer aldehyde derivatives
|
CA2859755C
(en)
|
2011-12-23 |
2021-04-20 |
Pfizer Inc. |
Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
|
WO2013109994A1
(en)
|
2012-01-20 |
2013-07-25 |
Sea Lane Biotechnologies, Llc |
Surrobody cojugates
|
SG11201405131XA
(en)
|
2012-02-24 |
2014-10-30 |
Stemcentrx Inc |
Dll3 modulators and methods of use
|
AR090549A1
(es)
|
2012-03-30 |
2014-11-19 |
Genentech Inc |
Anticuerpos anti-lgr5 e inmunoconjugados
|
US9816066B2
(en)
|
2012-04-24 |
2017-11-14 |
The Regents Of The University Of California |
Method for delivery of small molecules and proteins across the cell wall of algae using molecular transporters
|
US9056910B2
(en)
|
2012-05-01 |
2015-06-16 |
Genentech, Inc. |
Anti-PMEL17 antibodies and immunoconjugates
|
NZ741211A
(en)
|
2012-05-15 |
2019-09-27 |
Seattle Genetics Inc |
Self-stabilizing linker conjugates
|
BR112015000439A2
(pt)
|
2012-07-09 |
2017-12-19 |
Genentech Inc |
imunoconjugado , formulação farmacêutica e métodos de tratamento de um indivíduo e de inibição da proliferação
|
MX2015000314A
(es)
|
2012-07-09 |
2015-04-10 |
Genentech Inc |
Anticuerpos anti-cd79b e inmunoconjugados.
|
CN103566377A
(zh)
|
2012-07-18 |
2014-02-12 |
上海博笛生物科技有限公司 |
癌症的靶向免疫治疗
|
US9382329B2
(en)
|
2012-08-14 |
2016-07-05 |
Ibc Pharmaceuticals, Inc. |
Disease therapy by inducing immune response to Trop-2 expressing cells
|
SG11201501286PA
(en)
|
2012-08-23 |
2015-05-28 |
Agensys Inc |
Antibody drug conjugates (adc) that bind to 158p1d7 proteins
|
AU2012395148B2
(en)
|
2012-11-24 |
2016-10-27 |
Hangzhou Dac Biotech Co., Ltd. |
Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules
|
US10137196B2
(en)
|
2012-12-13 |
2018-11-27 |
Immunomedics, Inc. |
Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
|
US9931417B2
(en)
|
2012-12-13 |
2018-04-03 |
Immunomedics, Inc. |
Antibody-SN-38 immunoconjugates with a CL2A linker
|
WO2015012904A2
(en)
|
2012-12-13 |
2015-01-29 |
Immunomedics, Inc. |
Antibody-sn-38 immunoconjugates with a cl2a linker
|
US9492566B2
(en)
|
2012-12-13 |
2016-11-15 |
Immunomedics, Inc. |
Antibody-drug conjugates and uses thereof
|
KR20230078823A
(ko)
|
2012-12-13 |
2023-06-02 |
이뮤노메딕스, 인코오포레이티드 |
개선된 효능 및 감소된 독성을 위한 항체 및 sn-38의 면역컨쥬게이트의 투약
|
US10206918B2
(en)
|
2012-12-13 |
2019-02-19 |
Immunomedics, Inc. |
Efficacy of anti-HLA-DR antiboddy drug conjugate IMMU-140 (hL243-CL2A-SN-38) in HLA-DR positive cancers
|
US10413539B2
(en)
|
2012-12-13 |
2019-09-17 |
Immunomedics, Inc. |
Therapy for metastatic urothelial cancer with the antibody-drug conjugate, sacituzumab govitecan (IMMU-132)
|
US10744129B2
(en)
|
2012-12-13 |
2020-08-18 |
Immunomedics, Inc. |
Therapy of small-cell lung cancer (SCLC) with a topoisomerase-I inhibiting antibody-drug conjugate (ADC) targeting Trop-2
|
US11053316B2
(en)
|
2013-01-14 |
2021-07-06 |
Xencor, Inc. |
Optimized antibody variable regions
|
US9701759B2
(en)
|
2013-01-14 |
2017-07-11 |
Xencor, Inc. |
Heterodimeric proteins
|
US9605084B2
(en)
|
2013-03-15 |
2017-03-28 |
Xencor, Inc. |
Heterodimeric proteins
|
US10131710B2
(en)
|
2013-01-14 |
2018-11-20 |
Xencor, Inc. |
Optimized antibody variable regions
|
JP6618362B2
(ja)
|
2013-01-14 |
2019-12-11 |
ゼンコア インコーポレイテッド |
新規異種二量体タンパク質
|
US10487155B2
(en)
|
2013-01-14 |
2019-11-26 |
Xencor, Inc. |
Heterodimeric proteins
|
US10968276B2
(en)
|
2013-03-12 |
2021-04-06 |
Xencor, Inc. |
Optimized anti-CD3 variable regions
|
US9738722B2
(en)
|
2013-01-15 |
2017-08-22 |
Xencor, Inc. |
Rapid clearance of antigen complexes using novel antibodies
|
MX2015010682A
(es)
|
2013-02-22 |
2016-05-31 |
Stemcentrx Inc |
Nuevos conjugados de anticuerpos y usos de los mismos.
|
PE20151672A1
(es)
|
2013-03-14 |
2015-11-27 |
Genentech Inc |
Anticuerpos e inmunoconjugados anti-b7-h4
|
US9562099B2
(en)
|
2013-03-14 |
2017-02-07 |
Genentech, Inc. |
Anti-B7-H4 antibodies and immunoconjugates
|
KR102413494B1
(ko)
|
2013-03-15 |
2022-06-24 |
젠코어 인코포레이티드 |
이형이량체 단백질
|
US10858417B2
(en)
|
2013-03-15 |
2020-12-08 |
Xencor, Inc. |
Heterodimeric proteins
|
DK2970486T3
(en)
|
2013-03-15 |
2018-08-06 |
Xencor Inc |
MODULATION OF T-CELLS WITH BISPECIFIC ANTIBODIES AND FC-FUSIONS
|
US10106624B2
(en)
|
2013-03-15 |
2018-10-23 |
Xencor, Inc. |
Heterodimeric proteins
|
US10519242B2
(en)
|
2013-03-15 |
2019-12-31 |
Xencor, Inc. |
Targeting regulatory T cells with heterodimeric proteins
|
MX368258B
(es)
|
2013-03-15 |
2019-09-25 |
Zymeworks Inc |
Compuestos citotoxicos y antimitoticos y metodos de uso de los mismos.
|
US11253606B2
(en)
|
2013-07-23 |
2022-02-22 |
Immunomedics, Inc. |
Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
|
RU2679657C2
(ru)
|
2013-08-01 |
2019-02-12 |
Эдженсис, Инк. |
Конъюгаты антител с лекарственными средствами, связывающиеся с белками cd37
|
MX2016002547A
(es)
|
2013-08-28 |
2016-06-17 |
Stemcentrx Inc |
Metodos de conjugacion de anticuerpos especificos de sitio y composiciones.
|
SG11201601416VA
(en)
|
2013-08-28 |
2016-03-30 |
Stemcentrx Inc |
Novel sez6 modulators and methods of use
|
BR112016004450A2
(pt)
|
2013-09-17 |
2017-10-17 |
Genentech Inc |
métodos para tratar uma doença, para aumentar a eficácia de um tratamento, para adiar e/ou prevenir desenvolvimento da reincidência e/ou resistência de uma doença, para aumentar a sensibilidade a um inibidor, para estender o período de sensibilidade a um inibidor e para estender a duração de resposta a um inibidor
|
JP6657075B2
(ja)
|
2013-10-11 |
2020-03-04 |
オックスフォード バイオセラピューティックス リミテッドOxford Biotherapeutics Ltd |
がん治療のためのly75に対する複合抗体
|
CN105813654B
(zh)
|
2013-10-11 |
2019-05-31 |
美国政府(由卫生和人类服务部的部长所代表) |
Tem8抗体及其用途
|
KR102645430B1
(ko)
|
2013-10-15 |
2024-03-11 |
씨젠 인크. |
개선된 리간드-약물 컨쥬게이트 약물동력학을 위한 peg화된 약물-링커
|
WO2015061206A2
(en)
|
2013-10-21 |
2015-04-30 |
North Carolina State University |
Methods and constructs for compound delivery
|
WO2015069922A2
(en)
|
2013-11-06 |
2015-05-14 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Alk antibodies, conjugates, and chimeric antigen receptors, and their use
|
US10457976B2
(en)
|
2013-11-25 |
2019-10-29 |
Seattle Genetics, Inc. |
Preparing antibodies from CHO cell cultures for conjugation
|
MX2016007576A
(es)
|
2013-12-13 |
2016-10-03 |
Genentech Inc |
Anticuerpos e inmunoconjugados anti-cd33.
|
WO2015095223A2
(en)
|
2013-12-16 |
2015-06-25 |
Genentech, Inc. |
Peptidomimetic compounds and antibody-drug conjugates thereof
|
MX2016008444A
(es)
|
2013-12-27 |
2017-01-11 |
Zymeworks Inc |
Sistemas de enlace que contienen sulfonamida para conjugados de farmacos.
|
WO2015103549A1
(en)
|
2014-01-03 |
2015-07-09 |
The United States Of America, As Represented By The Secretary Department Of Health And Human Services |
Neutralizing antibodies to hiv-1 env and their use
|
JP2017502068A
(ja)
|
2014-01-10 |
2017-01-19 |
シャンハイ バーディー バイオテック インコーポレイテッド |
Her2陽性腫瘍を処置するための化合物及び組成物
|
WO2015106224A2
(en)
|
2014-01-12 |
2015-07-16 |
Hugh Mctavish |
Fusion proteins containing insulin-like growth factor-1 and epidermal growth factor and variants thereof and uses thereof
|
CR20160437A
(es)
|
2014-02-21 |
2017-02-20 |
Abbvie Stemcentrx Llc |
Conjugados de anticuerpos anti-drosophila similar a delta 3 (anti-dll3) y medicamentos para uso en el tratamiento contra melanoma
|
CA2938919C
(en)
|
2014-02-28 |
2020-12-29 |
Hangzhou Dac Biotech Co., Ltd |
Charged linkers and their uses for conjugation
|
SG10201808837RA
(en)
|
2014-03-21 |
2018-11-29 |
Abbvie Inc |
Anti-egfr antibodies and antibody drug conjugates
|
EP3122376A4
(en)
|
2014-03-27 |
2017-12-20 |
The Brigham and Women's Hospital, Inc. |
Metabolically-activated drug conjugates to overcome resistance in cancer therapy
|
SG11201607983YA
(en)
|
2014-03-28 |
2016-10-28 |
Xencor Inc |
Bispecific antibodies that bind to cd38 and cd3
|
MX2016015162A
(es)
|
2014-05-22 |
2017-03-03 |
Genentech Inc |
Anticuerpos anti - gpc3 e inmunoconjugados.
|
EP3194449A1
(en)
|
2014-07-24 |
2017-07-26 |
Xencor, Inc. |
Rapid clearance of antigen complexes using novel antibodies
|
CN112587672A
(zh)
|
2014-09-01 |
2021-04-02 |
博笛生物科技有限公司 |
用于治疗肿瘤的抗-pd-l1结合物
|
AR101848A1
(es)
|
2014-09-12 |
2017-01-18 |
Genentech Inc |
Anticuerpos de anti-b7-h4 e inmunoconjugados
|
SG11201701128YA
(en)
|
2014-09-12 |
2017-03-30 |
Genentech Inc |
Cysteine engineered antibodies and conjugates
|
US9751946B2
(en)
|
2014-09-12 |
2017-09-05 |
Genentech, Inc. |
Anti-CLL-1 antibodies and immunoconjugates
|
CA2957238C
(en)
|
2014-09-12 |
2024-02-20 |
Genentech, Inc. |
Anti-her2 antibodies and immunoconjugates
|
WO2016040825A1
(en)
|
2014-09-12 |
2016-03-17 |
Genentech, Inc. |
Anthracycline disulfide intermediates, antibody-drug conjugates and methods
|
EP3194421B1
(en)
|
2014-09-17 |
2021-11-03 |
Zymeworks Inc. |
Cytotoxic and anti-mitotic compounds, and methods of using the same
|
WO2016049214A1
(en)
|
2014-09-23 |
2016-03-31 |
Genentech, Inc. |
METHOD OF USING ANTI-CD79b IMMUNOCONJUGATES
|
EP3786182A1
(en)
|
2014-11-19 |
2021-03-03 |
Axon Neuroscience SE |
Humanized tau antibodies in alzheimer's disease
|
WO2016086196A2
(en)
|
2014-11-26 |
2016-06-02 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and cd38
|
US10259887B2
(en)
|
2014-11-26 |
2019-04-16 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and tumor antigens
|
CN116333153A
(zh)
|
2014-11-26 |
2023-06-27 |
森科股份有限公司 |
结合cd3和肿瘤抗原的异二聚体抗体
|
EP3237449A2
(en)
|
2014-12-22 |
2017-11-01 |
Xencor, Inc. |
Trispecific antibodies
|
US10227411B2
(en)
|
2015-03-05 |
2019-03-12 |
Xencor, Inc. |
Modulation of T cells with bispecific antibodies and FC fusions
|
AU2016226083A1
(en)
|
2015-03-05 |
2017-10-12 |
Sirenas Llc |
Cyclic peptide analogs and conjugates thereof
|
WO2016145099A1
(en)
|
2015-03-09 |
2016-09-15 |
Agensys, Inc. |
Antibody drug conjugates (adc) that bind to flt3 proteins
|
AU2016246737B2
(en)
|
2015-04-07 |
2019-11-21 |
Cornell University |
Nanoparticle immunoconjugates
|
JP6746845B2
(ja)
|
2015-04-22 |
2020-08-26 |
イミューノメディクス、インコーポレイテッドImmunomedics, Inc. |
循環trop−2陽性癌細胞の単離、検出、診断及び/または特徴付け
|
EP3091033A1
(en)
|
2015-05-06 |
2016-11-09 |
Gamamabs Pharma |
Anti-human-her3 antibodies and uses thereof
|
CA2986437A1
(en)
|
2015-06-08 |
2016-12-15 |
Debiopharm International, S.A. |
Anti-cd37 immunoconjugate and anti-cd20 antibody combinations
|
JP7269733B2
(ja)
|
2015-06-12 |
2023-05-09 |
レンティジェン・テクノロジー・インコーポレイテッド |
操作されたt細胞を用いて癌を処置するための方法
|
US10195175B2
(en)
|
2015-06-25 |
2019-02-05 |
Immunomedics, Inc. |
Synergistic effect of anti-Trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors
|
HUE063320T2
(hu)
|
2015-06-30 |
2024-01-28 |
Seagen Inc |
Anti-NTB-A antitestek és kapcsolódó készítmények és eljárások
|
CN108449940B
(zh)
|
2015-07-12 |
2021-06-08 |
杭州多禧生物科技有限公司 |
与细胞结合分子的共轭偶联的桥连接体
|
US9839687B2
(en)
|
2015-07-15 |
2017-12-12 |
Suzhou M-Conj Biotech Co., Ltd. |
Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
|
KR20180042423A
(ko)
|
2015-08-28 |
2018-04-25 |
데비오팜 인터네셔날 에스 에이 |
Cd37 의 검출을 위한 항체 및 검정
|
EP3347047A1
(en)
|
2015-09-09 |
2018-07-18 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Expression vector delivery system and use thereof for inducing an immune response
|
CA2997809A1
(en)
|
2015-10-07 |
2017-04-13 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Il-7r-alpha specific antibodies for treating acute lymphoblastic leukemia
|
ES2778651T3
(es)
|
2015-10-09 |
2020-08-11 |
Miltenyi Biotec Technology Inc |
Receptores de antígeno quimérico y métodos de uso
|
WO2017066714A1
(en)
|
2015-10-16 |
2017-04-20 |
Compugen Ltd. |
Anti-vsig1 antibodies and drug conjugates
|
MA43354A
(fr)
|
2015-10-16 |
2018-08-22 |
Genentech Inc |
Conjugués médicamenteux à pont disulfure encombré
|
JP7058219B2
(ja)
|
2015-12-07 |
2022-04-21 |
ゼンコア インコーポレイテッド |
Cd3及びpsmaに結合するヘテロ二量体抗体
|
US20170224837A1
(en)
|
2016-02-10 |
2017-08-10 |
Immunomedics, Inc. |
Combination of abcg2 inhibitors with sacituzumab govitecan (immu-132) overcomes resistance to sn-38 in trop-2 expressing cancers
|
EP3419655A1
(en)
|
2016-02-27 |
2019-01-02 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Peptide vaccines comprising self-assembling polymer nanoparticles
|
MA45280B1
(fr)
|
2016-03-02 |
2021-08-31 |
Eisai R&D Man Co Ltd |
Conjugués anticorps-médicament à base d'éribuline et leurs procédés d'utilisation
|
MA45324A
(fr)
|
2016-03-15 |
2019-01-23 |
Seattle Genetics Inc |
Polythérapie utilisant un adc-liv1 et un agent chimiothérapeutique
|
MA43835A
(fr)
|
2016-03-25 |
2018-11-28 |
Seattle Genetics Inc |
Procédé de préparation de lieurs de médicaments pégylés et leurs intermédiaires
|
JP2019522960A
(ja)
|
2016-04-21 |
2019-08-22 |
アッヴィ・ステムセントルクス・エル・エル・シー |
新規の抗bmpr1b抗体及び使用方法
|
WO2017189483A1
(en)
|
2016-04-25 |
2017-11-02 |
The Johns Hopkins University |
Znt8 assays for drug development and pharmaceutical compositions
|
JP7379795B2
(ja)
|
2016-04-27 |
2023-11-15 |
イミューノメディクス、インコーポレイテッド |
チェックポイント阻害薬に再発/耐性を示す腫瘍を治療するための抗Trop-2-SN-38抗体薬物複合体の効果
|
TW201805307A
(zh)
|
2016-05-13 |
2018-02-16 |
美商拜奧亞特拉公司 |
抗-ror2抗體、抗體片段、其免疫結合物及其用途
|
WO2017205741A1
(en)
|
2016-05-27 |
2017-11-30 |
Genentech, Inc. |
Bioanalytical method for the characterization of site-specific antibody-drug conjugates
|
CN109562169A
(zh)
|
2016-06-08 |
2019-04-02 |
艾伯维公司 |
抗cd98抗体及抗体药物偶联物
|
CA3027046A1
(en)
|
2016-06-08 |
2017-12-14 |
Abbvie Inc. |
Anti-cd98 antibodies and antibody drug conjugates
|
MX2018015277A
(es)
|
2016-06-08 |
2019-09-06 |
Abbvie Inc |
Anticuerpos anti-b7-h3 y conjugados de anticuerpo y farmaco.
|
RU2764651C2
(ru)
|
2016-06-08 |
2022-01-19 |
Эббви Инк. |
Антитела к в7-н3 и конъюгаты антитела и лекарственного средства
|
CN109641962A
(zh)
|
2016-06-08 |
2019-04-16 |
艾伯维公司 |
抗b7-h3抗体和抗体药物偶联物
|
KR20230054508A
(ko)
|
2016-06-14 |
2023-04-24 |
젠코어 인코포레이티드 |
이중특이적 체크포인트 억제제 항체
|
MX2018016265A
(es)
|
2016-06-28 |
2019-07-04 |
Xencor Inc |
Anticuerpos heterodimericos que se unen al receptor 2 de somatostatina.
|
CN109963871A
(zh)
|
2016-08-05 |
2019-07-02 |
豪夫迈·罗氏有限公司 |
具有激动活性的多价及多表位抗体以及使用方法
|
SG11201900699QA
(en)
|
2016-08-09 |
2019-02-27 |
Seattle Genetics Inc |
Drug conjugates with self-stabilizing linkers having improved physiochemical properties
|
US10793632B2
(en)
|
2016-08-30 |
2020-10-06 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
US11254705B2
(en)
|
2016-09-02 |
2022-02-22 |
Sirenas Llc |
Cyclic peptide analogs and conjugates thereof
|
WO2018045325A1
(en)
|
2016-09-02 |
2018-03-08 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with duocars
|
WO2018071918A1
(en)
|
2016-10-14 |
2018-04-19 |
Xencor, Inc. |
Bispecific heterodimeric fusion proteins containing il-15/il-15ralpha fc-fusion proteins and pd-1 antibody fragments
|
WO2018083633A1
(en)
|
2016-11-02 |
2018-05-11 |
Debiopharm International, S.A. |
Methods for improving anti-cd37 immunoconjugate therapy
|
EP3888691A1
(en)
|
2016-11-14 |
2021-10-06 |
Hangzhou Dac Biotech Co., Ltd. |
Conjugation linkers, cell binding molecule-drug conjugates containing the likers, methods of making and uses such conjugates with the linkers
|
CN110023334B
(zh)
|
2016-11-21 |
2023-11-14 |
科雅博有限责任公司 |
抗gp73抗体和免疫偶联物
|
AU2018205372B2
(en)
|
2017-01-09 |
2020-08-06 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-mesothelin immunotherapy
|
CN110392697A
(zh)
|
2017-03-02 |
2019-10-29 |
国家医疗保健研究所 |
对nectin-4具有特异性的抗体及其用途
|
GB201703876D0
(en)
|
2017-03-10 |
2017-04-26 |
Berlin-Chemie Ag |
Pharmaceutical combinations
|
CN112695050A
(zh)
|
2017-03-24 |
2021-04-23 |
莱蒂恩技术公司 |
用于用抗cd33免疫疗法治疗癌症的组合物和方法
|
JP2020512312A
(ja)
|
2017-03-24 |
2020-04-23 |
シアトル ジェネティックス, インコーポレイテッド |
グルクロニド薬物−リンカーの調製のためのプロセスおよびその中間体
|
RU2758234C2
(ru)
|
2017-03-27 |
2021-10-26 |
Иммьюномедикс, Инк. |
ЛЕЧЕНИЕ ТРИЖДЫ НЕГАТИВНОГО РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ, ХАРАКТЕРИЗУЮЩЕГОСЯ ЭКСПРЕССИЕЙ Trop-2, С ПОМОЩЬЮ САЦИТУЗУМАБА ГОВИТЕКАНА И ИНГИБИТОРА Rad51
|
EP3606964A4
(en)
|
2017-04-03 |
2020-12-09 |
Immunomedics, Inc. |
SUBCUTANE ADMINISTRATION OF ANTIBODY DRUG CONJUGATES FOR CANCER THERAPY
|
IL302880A
(en)
|
2017-04-04 |
2023-07-01 |
Avidea Tech Inc |
Peptide-based ingredients, production methods, and their uses for inducing an immune response
|
AU2018250336A1
(en)
|
2017-04-07 |
2019-09-26 |
Juno Therapeutics, Inc. |
Engineered cells expressing prostate-specific membrane antigen (PSMA) or a modified form thereof and related methods
|
EP3612567A4
(en)
|
2017-04-19 |
2020-11-11 |
Bluefin Biomedicine, Inc. |
ANTI-VTCN1 ANTIBODIES AND ANTIBODY INGREDIENT CONJUGATES
|
CN110637036A
(zh)
|
2017-04-28 |
2019-12-31 |
味之素株式会社 |
具有针对可溶性蛋白质的亲和性物质、切割性部分及反应性基团的化合物或其盐
|
CN110636867B
(zh)
|
2017-05-21 |
2023-09-05 |
Igf肿瘤公司 |
胰岛素样生长因子——用于治疗骨髓增生异常综合症的化学治疗缀合物
|
WO2019006472A1
(en)
|
2017-06-30 |
2019-01-03 |
Xencor, Inc. |
TARGETED HETETRODIMERIC FUSION PROTEINS CONTAINING IL-15 / IL-15RA AND ANTIGEN-BINDING DOMAINS
|
WO2019014044A1
(en)
|
2017-07-12 |
2019-01-17 |
The Johns Hopkins University |
ZNT8 AUTO-ANTIGEN BASED ON PROTEOLIPOSOMES FOR THE DIAGNOSIS OF TYPE 1 DIABETES
|
WO2019028051A1
(en)
|
2017-07-31 |
2019-02-07 |
Lentigen Technology, Inc. |
COMPOSITIONS AND METHODS FOR TREATING CANCER BY ANTI-CD19 / CD20 IMMUNOTHERAPY
|
WO2019030574A1
(en)
|
2017-08-10 |
2019-02-14 |
Cerenis Therapeutics Holding |
CARGOMÈRES
|
EP3681903B1
(en)
|
2017-09-15 |
2023-07-19 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-cd19 immunotherapy
|
EP3697426B1
(en)
|
2017-10-16 |
2023-07-26 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-cd22 immunotherapy
|
JP7381478B2
(ja)
|
2017-10-23 |
2023-11-15 |
マブリンク ビオシオンス |
単一分子量ポリサルコシンを含むリガンド-薬物-複合体
|
EP3706793A1
(en)
|
2017-11-08 |
2020-09-16 |
Xencor, Inc. |
Bispecific and monospecific antibodies using novel anti-pd-1 sequences
|
US10981992B2
(en)
|
2017-11-08 |
2021-04-20 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
EA202091360A1
(ru)
|
2017-12-01 |
2020-08-24 |
Сиэтл Дженетикс, Инк. |
Гуманизированные анти-liv1 антитела для лечения рака молочной железы
|
SG11202004864TA
(en)
|
2017-12-01 |
2020-06-29 |
Seattle Genetics Inc |
Cd47 antibodies and uses thereof for treating cancer
|
MX2020006322A
(es)
|
2017-12-19 |
2020-09-18 |
Xencor Inc |
Proteinas de fusion il-2 fc modificadas.
|
WO2019126464A2
(en)
|
2017-12-20 |
2019-06-27 |
Lentigen Technology, Inc. |
Compositions and methods for treating hiv/aids with immunotherapy
|
WO2019180150A1
(en)
|
2018-03-22 |
2019-09-26 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for modulating innate lymphoid cell activity, antibody drug conjugates and uses in therapy
|
WO2019183438A1
(en)
|
2018-03-23 |
2019-09-26 |
Seattle Genetics, Inc. |
Use of antibody drug conjugates comprising tubulin disrupting agents to treat solid tumor
|
BR112020018868A2
(pt)
|
2018-03-28 |
2021-01-26 |
Axon Neuroscience Se |
métodos baseados em anticorpo para detectar e tratar doença de alzheimer
|
CN112469477A
(zh)
|
2018-04-04 |
2021-03-09 |
Xencor股份有限公司 |
与成纤维细胞活化蛋白结合的异源二聚体抗体
|
JP2021520829A
(ja)
|
2018-04-18 |
2021-08-26 |
ゼンコア インコーポレイテッド |
IL−15/IL−15RA Fc融合タンパク質およびTIM−3抗原結合ドメインを含む、TIM−3標的化ヘテロ二量体融合タンパク質
|
CA3097593A1
(en)
|
2018-04-18 |
2019-10-24 |
Xencor, Inc. |
Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof
|
US20210113705A1
(en)
|
2018-05-22 |
2021-04-22 |
Avidea Technologies, Inc. |
Improved methods of manufacturing peptide-based vaccines
|
CA3099920A1
(en)
|
2018-06-01 |
2019-12-05 |
Eisai R&D Management Co., Ltd. |
Splicing modulator antibody-drug conjugates and methods of use
|
EP3811978A4
(en)
|
2018-06-14 |
2022-03-16 |
Ajinomoto Co., Inc. |
SUBSTANCE HAVING AFFINITY FOR AN ANTIBODY, AND COMPOUND OR SALT THEREOF HAVING A BIOORTHOGONAL FUNCTIONAL GROUP
|
WO2019240287A1
(ja)
|
2018-06-14 |
2019-12-19 |
味の素株式会社 |
抗体に対する親和性物質、切断性部分および反応性基を有する化合物またはその塩
|
GB201809746D0
(en)
|
2018-06-14 |
2018-08-01 |
Berlin Chemie Ag |
Pharmaceutical combinations
|
CA3104386A1
(en)
|
2018-07-02 |
2020-01-09 |
Amgen Inc. |
Anti-steap1 antigen-binding protein
|
US10844128B2
(en)
|
2018-09-20 |
2020-11-24 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-CD123 immunotherapy
|
CA3114349A1
(en)
|
2018-09-26 |
2020-04-02 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-cd19/cd22 immunotherapy
|
EP3861016A2
(en)
|
2018-10-03 |
2021-08-11 |
Xencor, Inc. |
Il-12 heterodimeric fc-fusion proteins
|
US20210393523A1
(en)
|
2018-10-03 |
2021-12-23 |
Avldea Technologies, Inc. |
Aromatic ring substituted amphiphilic polymers as drug delivery systems
|
EP3882261A4
(en)
|
2018-10-31 |
2023-02-08 |
Ajinomoto Co., Inc. |
COMPOUND COMPRISING A SUBSTANCE HAVING AN AFFINITY FOR AN ANTIBODY, CLEAVAGE SITE AND CORRESPONDING REACTIVE GROUP OR SALT
|
JP2022513682A
(ja)
|
2018-11-30 |
2022-02-09 |
レンティジェン・テクノロジー・インコーポレイテッド |
抗cd38免疫療法によりがんを処置するための組成物および方法
|
JP2022512401A
(ja)
|
2018-12-13 |
2022-02-03 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
ハーボキシジエンスプライシング調節薬抗体-薬物コンジュゲート及びその使用方法
|
WO2020154672A1
(en)
*
|
2019-01-25 |
2020-07-30 |
Yale University |
Anticancer drugs and methods of making and using same
|
JP2022519273A
(ja)
|
2019-02-05 |
2022-03-22 |
シージェン インコーポレイテッド |
抗cd228抗体及び抗体薬物コンジュゲート
|
SG11202109406TA
(en)
|
2019-03-01 |
2021-09-29 |
Xencor Inc |
Heterodimeric antibodies that bind enpp3 and cd3
|
CN113924103A
(zh)
|
2019-03-06 |
2022-01-11 |
莱蒂恩技术公司 |
用于用自驱动的嵌合抗原受体来治疗癌症的组合物和方法
|
WO2020191342A1
(en)
|
2019-03-20 |
2020-09-24 |
The Regents Of The University Of California |
Claudin-6 antibodies and drug conjugates
|
CN114206934A
(zh)
|
2019-03-20 |
2022-03-18 |
加利福尼亚大学董事会 |
密封蛋白-6双特异性抗体
|
WO2020214858A1
(en)
|
2019-04-17 |
2020-10-22 |
Avidea Technologies, Inc. |
Compositions and methods of manufacturing star polymers for ligand display and/or drug delivery
|
US20200407440A1
(en)
|
2019-04-24 |
2020-12-31 |
Magenta Therapeutics, Inc. |
Amatoxin antibody-drug conjugates and uses thereof
|
CA3140102A1
(en)
|
2019-05-30 |
2020-12-03 |
Dina SCHNEIDER |
Compositions and methods for treating cancer with anti-bcma immunotherapy
|
WO2020247572A1
(en)
|
2019-06-05 |
2020-12-10 |
Seattle Genetics, Inc. |
Masked antibody formulations
|
AR119097A1
(es)
|
2019-06-05 |
2021-11-24 |
Seattle Genetics Inc |
Métodos de purificación de anticuerpos enmascarados
|
AU2020299382A1
(en)
|
2019-07-02 |
2022-01-20 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Monoclonal antibodies that bind EGFRvIII and their use
|
BR112022001045A2
(pt)
|
2019-07-22 |
2022-07-19 |
Seagen Inc |
Método para tratar um indivíduo com ou em risco de desenvolver um câncer associado a liv1, e, kit
|
BR112022005114A2
(pt)
|
2019-10-04 |
2022-06-21 |
Seagen Inc |
Anticorpo, composição farmacêutica, métodos para tratar câncer e para produzir um conjugado anticorpo-fármaco e um anticorpo, ácido nucleico, vetor, célula hospedeira, e, conjugado anticorpo-fármaco
|
US20240058466A1
(en)
|
2019-10-04 |
2024-02-22 |
TAE Life Sciences |
Antibody Compositions Comprising Fc Mutations and Site-Specific Conjugation Properties For Use In Treating Cancer, Immunological Disorders, and Methods Thereof
|
EP3812008A1
(en)
|
2019-10-23 |
2021-04-28 |
Gamamabs Pharma |
Amh-competitive antagonist antibody
|
EP4072682A1
(en)
|
2019-12-09 |
2022-10-19 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Antibodies having specificity to her4 and uses thereof
|
WO2021142086A1
(en)
|
2020-01-08 |
2021-07-15 |
Synthis Therapeutics, Inc. |
Alk5 inhibitor conjugates and uses thereof
|
WO2021224186A1
(en)
|
2020-05-04 |
2021-11-11 |
Institut Curie |
New pyridine derivatives as radiosensitizers
|
CA3180683A1
(en)
|
2020-05-12 |
2021-11-18 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
New method to treat cutaneous t-cell lymphomas and tfh derived lymphomas
|
US11919956B2
(en)
|
2020-05-14 |
2024-03-05 |
Xencor, Inc. |
Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3
|
AR122546A1
(es)
|
2020-06-05 |
2022-09-21 |
Eisai R&D Man Co Ltd |
Conjugados de anticuerpo anti bcma-fármaco y métodos de uso
|
EP4163294A1
(en)
|
2020-06-09 |
2023-04-12 |
Ajinomoto Co., Inc. |
Modified ferritin and method for producing same
|
WO2021262723A1
(en)
|
2020-06-22 |
2021-12-30 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with tslpr-cd19 or tslpr-cd22 immunotherapy
|
MX2023001143A
(es)
|
2020-08-04 |
2023-02-22 |
Seagen Inc |
Anticuerpos anti-cd228 y conjugados de anticuerpos-farmacos.
|
EP3970752A1
(en)
|
2020-09-17 |
2022-03-23 |
Merck Patent GmbH |
Molecules with solubility tag and related methods
|
CA3193244A1
(en)
|
2020-09-22 |
2022-03-31 |
Geoffrey Martin Lynn |
Compositions and methods of manufacturing amphiphilic block copolymers that form nanoparticles in situ
|
KR20230079154A
(ko)
|
2020-09-28 |
2023-06-05 |
씨젠 인크. |
암 치료를 위한 인간화 항-liv1 항체
|
CA3197168A1
(en)
|
2020-10-01 |
2022-04-07 |
Abionyx Pharma Sa |
Methods for treating eye diseases using lipid binding protein-based complexes
|
US20230390406A1
(en)
|
2020-10-19 |
2023-12-07 |
Vaccitech North America, Inc. |
Star Polymer Drug Conjugates
|
US20230303604A1
(en)
|
2020-10-20 |
2023-09-28 |
Institut Curie |
Metallic trans-(n-heterocyclic carbene)-amine-platinum complexes and uses thereof for treating cancer
|
EP4240397A1
(en)
|
2020-11-05 |
2023-09-13 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-cd19/cd22 immunotherapy
|
KR20230133289A
(ko)
|
2021-01-18 |
2023-09-19 |
아지노모토 가부시키가이샤 |
화합물 또는 이의 염, 및 이들에 의해 얻어지는 항체
|
AU2022208654A1
(en)
|
2021-01-18 |
2023-08-03 |
Ajinomoto Co., Inc. |
Compound or salt thereof, and antibody produced using same
|
UY39610A
(es)
|
2021-01-20 |
2022-08-31 |
Abbvie Inc |
Conjugados anticuerpo-fármaco anti-egfr
|
IL305174A
(en)
|
2021-02-16 |
2023-10-01 |
Vaccitech North America Inc |
Self-assembly of nanoparticles based on amphiphilic peptides
|
AU2022232375A1
(en)
|
2021-03-09 |
2023-09-21 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and cldn6
|
EP4305065A1
(en)
|
2021-03-10 |
2024-01-17 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and gpc3
|
CA3212822A1
(en)
|
2021-03-11 |
2022-09-15 |
Ajinomoto Co., Inc. |
Compound or salt thereof, and antibody obtained by using the same
|
WO2022189618A1
(en)
|
2021-03-12 |
2022-09-15 |
Institut Curie |
Nitrogen-containing heterocycles as radiosensitizers
|
JPWO2022196675A1
(pt)
|
2021-03-16 |
2022-09-22 |
|
|
JP2024512478A
(ja)
|
2021-03-19 |
2024-03-19 |
ハイデルベルク ファルマ リサーチ ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Bリンパ球特異的アマトキシン抗体コンジュゲート
|
JP2024515934A
(ja)
|
2021-03-30 |
2024-04-11 |
レゴケム バイオサイエンシズ, インク. |
ヒトcldn18.2に対する抗体を含む抗体-薬物コンジュゲートおよびその使用
|
CN117279664A
(zh)
|
2021-04-10 |
2023-12-22 |
普方生物制药美国公司 |
Folr1结合剂、其偶联物及其使用方法
|
CA3216226A1
(en)
|
2021-04-15 |
2022-10-20 |
Abionyx Pharma Sa |
Use of lipid binding protein-based complexes in organ preservation solutions
|
JP2024516631A
(ja)
|
2021-04-23 |
2024-04-16 |
プロファウンドバイオ ユーエス カンパニー |
抗cd70抗体、そのコンジュゲートおよびこれを使用する方法
|
TW202320857A
(zh)
|
2021-07-06 |
2023-06-01 |
美商普方生物製藥美國公司 |
連接子、藥物連接子及其結合物及其使用方法
|
EP4370211A1
(en)
|
2021-07-14 |
2024-05-22 |
Seagen Inc. |
Antibody masking domains
|
WO2023049825A1
(en)
|
2021-09-24 |
2023-03-30 |
Seagen Inc. |
Improved antibody masking domains
|
CA3234692A1
(en)
|
2021-09-30 |
2023-04-06 |
Ajinomoto Co., Inc. |
Conjugate of antibody and functional substance or salt thereof, and antibody derivative and compound used in production of the same or salts thereof
|
WO2023089314A1
(en)
|
2021-11-18 |
2023-05-25 |
Oxford Biotherapeutics Limited |
Pharmaceutical combinations
|
WO2023092099A1
(en)
|
2021-11-19 |
2023-05-25 |
Ardeagen Corporation |
Gpc3 binding agents, conjugates thereof and methods of using the same
|
US11590169B1
(en)
|
2022-03-02 |
2023-02-28 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-CD123 immunotherapy
|
US20230338424A1
(en)
|
2022-03-02 |
2023-10-26 |
Lentigen Technology, Inc. |
Compositions and Methods for Treating Cancer with Anti-CD123 Immunotherapy
|
WO2023169896A1
(en)
|
2022-03-09 |
2023-09-14 |
Astrazeneca Ab |
BINDING MOLECULES AGAINST FRα
|
WO2023170216A1
(en)
|
2022-03-11 |
2023-09-14 |
Astrazeneca Ab |
A SCORING METHOD FOR AN ANTI-FRα ANTIBODY-DRUG CONJUGATE THERAPY
|
WO2023194797A1
(en)
|
2022-04-06 |
2023-10-12 |
Abionyx Pharma Sa |
Methods for treating eye diseases using lipid binding protein-based complexes
|
US20230355792A1
(en)
|
2022-04-07 |
2023-11-09 |
Heidelberg Pharma Research Gmbh |
Methods of improving the therapeutic index
|
WO2024026107A2
(en)
|
2022-07-28 |
2024-02-01 |
Lentigen Technology, Inc. |
Chimeric antigen receptor therapies for treating solid tumors
|
WO2024044743A1
(en)
|
2022-08-26 |
2024-02-29 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with fully human anti-cd20/cd19 immunotherapy
|
WO2024052503A1
(en)
|
2022-09-08 |
2024-03-14 |
Institut National de la Santé et de la Recherche Médicale |
Antibodies having specificity to ltbp2 and uses thereof
|
WO2024064714A2
(en)
|
2022-09-21 |
2024-03-28 |
Seagen Inc. |
Antibodies that bind cd228
|
WO2024092028A2
(en)
|
2022-10-25 |
2024-05-02 |
Vaccitech North America, Inc. |
Combination treatment regimes for treating cancer
|
WO2024092030A1
(en)
|
2022-10-25 |
2024-05-02 |
Vaccitech North America, Inc. |
Self-assembling nanoparticles
|
WO2024094688A1
(en)
|
2022-11-01 |
2024-05-10 |
Heidelberg Pharma Research Gmbh |
Anti-gucy2c antibody and uses thereof
|
WO2024097816A1
(en)
|
2022-11-03 |
2024-05-10 |
Seagen Inc. |
Anti-avb6 antibodies and antibody-drug conjugates and their use in the treatment of cancer
|